Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Cyteir Therapeutics $133.2 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Convey Holding Parent $186.7 million IPO
We advised the underwriters on the IPO and NYSE listing
Molecular Partners $64 million IPO
We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing
RAPT Therapeutics $143.7 million follow-on offering
We advised the joint book-running managers on the SEC-registered equity offering
CARsgen Therapeutics HK$3.1 billion IPO
We advised CARsgen Therapeutics on its IPO and HKEX listing
Apria $139.7 million stock offering
We advised the underwriters on the SEC-registered equity offering
Mathys sale to DJO
We are advising the Mathys family on the sale
Ayala Pharmaceuticals $20 million at-the-market offering
We advised the sales agent on the stock offering
Oak Street Health $747.2 million secondary offering
We advised the joint book-running managers on the equity offering
Esco Lifesciences $200 million Series A financing
We are advising Esco Lifesciences on its Series A financing